Recovery and tissue repair
TB-500
Editorial audit: October 15, 2026 · draft; scientific, medical and translation review pending
01What is reported
TB-500 is described for repair and in Wolverine-type combinations. Sources and sellers may use overlapping names for different materials.
02Proposed rationale
Claims borrow from thymosin beta-4 biology, including cell migration and repair. Evidence transfer requires the same molecule, not a shared name.
03What the research shows
The FDA scientific assessment distinguishes TB-500-related substances from full-length thymosin beta-4. A topical ocular trial of the latter does not test injected vendor TB-500.
04Limits and unknowns
The ocular trial’s primary endpoints were not positive, despite some secondary findings. Neither those findings nor laboratory data establish systemic repair-stack effectiveness.
05Questions to ask about the product
Which sequence and modifications were confirmed? The common name does not guarantee chemical identity, salt form or equivalence.
06Open research question
Can exposure records distinguish verified sequence, label-only identity and unknown material before outcomes are grouped?
Primary and regulatory references
- 1.
- 2.